RJA
FUSN

Raymond James & Associates’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

Raymond James & Associates’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-31,500
Closed -$78.8K – 4065
2023
Q4 		$78.8K Buy
+31,500
New +$153K ﹤0.01% 3667

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Raymond James & Associates's FUSN Position: Q1 2024 in Review

Raymond James & Associates sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 20,200 shares — an estimated $194K sold.

Raymond James & Associates first reported a position in FUSN in Q4 2023 and held it in 1 quarter. The position peaked at $194K in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • Raymond James & Associates reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 20,200 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $194K.
  • Raymond James & Associates first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q4 2023 and held it in 1 quarter.
  • Raymond James & Associates's Fusion Pharmaceuticals Inc. Common Shares position peaked at $194K in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.